The growing interest in psychedelic treatments for mental health has brought new hope to patients and providers seeking alternatives to conventional medications. Research involving psilocybin, ketamine, and MDMA has shown encouraging results for conditions such as depression, anxiety disorders, and post traumatic stress disorder. At the same time, ketamine clinics are expanding rapidly, and programs offering psychedelic-assisted therapy continue to emerge. However, as these treatments spread into clinical settings, the terminology used to describe them has not always kept pace. Many patients and clinicians have difficulty understanding what type of care is being offered and what role psychotherapy should play.
This confusion often results from the lack of clear definitions surrounding psychedelic-assisted therapy models. Treatments can vary widely, from medication-focused approaches to deeply structured therapeutic programs. Without shared language, it becomes challenging to compare research findings, guide regulations, or help patients understand what to expect.
Why Clear Definitions Matter
When people hear about psychedelic therapy, they may assume it requires an intense psychological journey guided by a therapist. In some cases this is true, but in others the medication is used for its biological effect alone, without emphasis on the psychedelic experience. For example, ketamine can be offered as a stand alone pharmacologic treatment for depression, functioning similarly to a fast acting antidepressant. Yet, in other settings, ketamine is paired with structured psychotherapy to support emotional processing and long-term change.
Without consistent terminology, it becomes difficult to evaluate which parts of the treatment are producing improvements. Is it the drug itself, the psychological experience it creates, or the therapeutic framework surrounding it?
Three Emerging Psychedelic-Assisted Therapy Models
Researchers have proposed three broad frameworks to better describe how these treatments are used:
1. Pharmacologic-Only Model
In this approach, the drug is used primarily for its biological effect. The goal is symptom reduction, and psychotherapy is not considered essential. Ketamine infusion for depression without added therapy is an example of this model. Here, the psychedelic or dissociative experience may occur, but it is not considered central to the treatment.
2. Experience-Supported Psychotherapy Model
In this model, the psychological effects of the drug are intentionally used to support therapy. The altered state of consciousness becomes part of the therapeutic process. The session environment, therapist presence, and emotional exploration are central to the treatment. Psilocybin sessions often fall within this category, where the experience itself is part of the healing process.
3. Combined Manualized Psychotherapy Model
This approach uses a structured form of psychotherapy that could exist on its own, but is enhanced with the addition of a psychedelic or ketamine session. Psychotherapy is specifically taught, structured, and replicable. The psychedelic element supports engagement and emotional openness, but the therapy model guides the long term change.
Moving Toward Clarity and Better Patient Care
Clear language helps ensure safer clinical practice, stronger study design, and more informed patient decision making. As psychedelics become more integrated into mental health care, defining treatment approaches will be essential for building trust, ensuring consistency, and supporting effective therapeutic outcomes.
Citations:
- Mitchell JM, Bogenschutz MP, Lilienstein A, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine. 2021;27(6):1025-1033. https://www.nature.com/articles/s41591-021-01336-3?utm_source=chatgpt.com
- McIntyre RS, Kwan ATH, Mansur RB, et al. Psychedelics for the treatment of psychiatric disorders: interpreting and translating available evidence and guidance for future research. American Journal of Psychiatry. 2025. https://pubmed.ncbi.nlm.nih.gov/39098356/